JP Morgan analyst Paul Chung downgrades Diebold Nixdorf (NYSE:DBD) from Neutral to Underweight.
Credit Suisse Maintains Outperform on Olema Pharmaceuticals, Lowers Price Target to $11
Credit Suisse analyst Richard Law maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Outperform and lowers the price target from $12 to $11.